Market Analysis by covering: Eli Lilly and Company, Vertex Pharmaceuticals Inc, Amgen Inc, abrdn Healthcare Opportunities Fund. Read 's Market Analysis on Investing.com ...

Amgen Inc. (NASDAQ:AMGN) is one of the best drug stocks to buy right now. Amgen Inc. (NASDAQ:AMGN) reported its fiscal Q2 2025 earnings on August 5, with total revenues increasing 9% to $9.2 billion compared to Q2 2024. GAAP earnings per share (EPS) rose 92% from $1.38 to $2.65, primarily attributed to higher revenues. Dogs of the Dow: Why Amgen’s (AMGN) Dividend Power Makes it a Standout Pick In a report released on September 5, Vamil Divan from Guggenheim maintained a Hold rating on Amgen Inc. (NASDAQ: ...

Key Takeaways Amgen is advancing MariTide in late-stage obesity studies with promising monthly dosing potential.Viking's VK2735 showed weight loss benefits but faced high dropout rates in its oral study.AMGN stock posts gains with rising estimates, while VKTX stock sinks with widening projected losses.Though Amgen (AMGN) and Viking Therapeutics (VKTX) do not currently market any obesity drugs, they are among the few biotechs that have shown immense potential in this space.Amgen boasts a strong presence in o ...

Building Resilience and Innovation: California’s Pharmaceutical Renaissance California is quietly staging a pharmaceutical renaissance, not of arts or culture this time, but of science, supply chains, and life-changing therapies. As the backbone of biopharma innovation in the U.S., the Golden State is becoming a place of industry transformation, embodied most recently by investments from Amgen and Gilead. A hub for pioneer science Amgen’s recent investment of $600 million to build a cutting-edge science ...

This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily Manufacturing Dive newsletter. International drugmakers are accelerating U.S. investments in an effort to be closer to key markets as tariff pressures complicate global trade and supply chains. Although pharmaceutical imports are exempt from U.S. tariffs, President Donald Trump has made a number of threats on the sector, floating the idea of raising tariffs as high as 250% last month. ...

iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios.It pays to be patient, especially when it comes to durable income growth stocks that fall into the value range. Acquiring quality assets at good prices is a ...

These drugmakers have competitive yields and have increased their dividends at a good clip.Between labor-market data and potential interest-rate cuts, Wall Street has a lot on its plate right now. In an environment like this one, it can be helpful to invest in solid, dividend-paying stocks -- and due to its non-cyclical nature, the healthcare sector is a good place to find some.Many medical products, including pharmaceutical drugs, perform relatively well even in tough economic times. That allows drugmakers ...

据卢特尼克表示，总统特朗普正在调动多个行政部门机构以实现这一目标。"我刚刚接到(卫生部长)博 比·肯尼迪的电话。我还接到了(美国医疗保险和医疗补助服务中心主任)梅赫迈特·奥兹的电话，他们都 和我说，'好吧，让我们开始推进这件事吧'。"卢特尼克在采访中补充说。 总部位于美国的吉利德(GILD.US)、百时美施贵宝(BMY.US)、强生(JNJ.US)、再生元(REGN.US)、安进 (AMGN.US)以及艾伯维(ABBV.US)，还包括总部位于欧洲的大型药企默克集团(Merck KGaA)、赛诺菲 (SNY.US)、葛兰素史克(GSK.US)、阿斯利康(AZN.US)、诺和诺德(NVO.US)、罗氏(RHHBY.US)以及诺 华(NVS.US)也收到了特朗普的来信。 "总统将会说，大型药品制造商们如果不在那边以更高的价格进行出售，就不能在这里销售。别再愿意 以那么低的价格卖给他们了。"卢特尼克在采访中表示。特朗普给药企们设定遵守该最惠国政策的最后 期限为9月29日，并且他在此之前作出了上述的坚定表态。 智通财经APP获悉，美国商务部长霍华德·卢特尼克近日在接受媒体采访时表示，总统唐纳德·特朗普正 在联合多个联邦 ...

The U.S. Food and Drug Administration will send out around 100 cease-and-desist enforcement notices and thousands of letters warning pharmaceutical companies that direct-to-consumer ads must comply wi... ...

PresentationTerence FlynnEquity Analyst Great. Good morning, everybody. I'm Terence Flynn, Morgan Stanley's large-cap U.S. biopharma analyst. Very pleased to be hosting Amgen this morning. Joining us from the company, we have Peter Griffith, the company's CFO; and Kave Niksefat, who is the company's SVP of Global Marketing. Thank you both so much for being here today. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you hav ...